163 related articles for article (PubMed ID: 36815381)
1. Outcomes in grade 3B follicular lymphoma: an international study led by the Australasian Lymphoma Alliance.
Barraclough A; England JT; Villa D; Wight J; Hapgood G; Conn J; Doo NW; Li EW; Gilbertson M; Shaw B; Bishton MJ; Saeed M; Ratnasingam S; Abeyakoon C; Chong G; Wai SH; Ku M; Lee HP; Fleming K; Tam C; Douglas G; Cheah CY; Ng ZY; Rolfe T; Mills AK; Hamad N; Cashman H; Gleeson M; Narayana M; Hawkes EA
Haematologica; 2023 Sep; 108(9):2444-2453. PubMed ID: 36815381
[TBL] [Abstract][Full Text] [Related]
2. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma.
Magnano L; Balagué O; Dlouhy I; Rovira J; Karube K; Pinyol M; Rivas-Delgado A; Costa D; Martínez-Trillos A; González-Farre B; Martínez-Pozo A; Giné E; Colomer D; Delgado J; Villamor N; Campo E; López-Guillermo A
Ann Oncol; 2017 Nov; 28(11):2799-2805. PubMed ID: 29045517
[TBL] [Abstract][Full Text] [Related]
3. Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma.
Qu Z; Zhang T; Gao F; Gong W; Cui Y; Qiu L; Qian Z; Zhou S; Meng B; Ren X; Li L; Wang X; Zhang H
Biomed Res Int; 2022; 2022():4379556. PubMed ID: 35655476
[TBL] [Abstract][Full Text] [Related]
4. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
[No Abstract] [Full Text] [Related]
5. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with
Uryu H; Mishima Y; Tsuyama N; Yokoyama M; Nishimura N; Fukuta T; Shirouchi Y; Okabe T; Inoue N; Takeuchi K; Terui Y
Leuk Lymphoma; 2021 Sep; 62(9):2141-2150. PubMed ID: 33749498
[TBL] [Abstract][Full Text] [Related]
6. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of VEGF-A and Microvessel Density in Diffuse Large B-Cell Lymphoma and Low-Grade Follicular Lymphoma.
Shahini L; Gašparov S; Petruševska G; Manxhuka Kerliu S; Veselaj F; Kurshumliu F; Kavaja F
Acta Clin Croat; 2017 Dec; 56(4):588-593. PubMed ID: 29590710
[TBL] [Abstract][Full Text] [Related]
8. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
9. Clinical, pathological and genetic features of follicular lymphoma grade 3A: a joint analysis of the German low-grade and high-grade lymphoma study groups GLSG and DSHNHL.
Koch K; Hoster E; Ziepert M; Unterhalt M; Ott G; Rosenwald A; Hansmann ML; Bernd W; Stein H; Pöschel V; Dreyling M; Trümper L; Löffler M; Schmitz N; Hiddemann W; Pfreundschuh M; Klapper W
Ann Oncol; 2016 Jul; 27(7):1323-9. PubMed ID: 27117536
[TBL] [Abstract][Full Text] [Related]
10. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
[TBL] [Abstract][Full Text] [Related]
11. Grade 3 Follicular Lymphoma: Outcomes in the Rituximab Era.
Mustafa Ali M; Rybicki L; Nomani L; Rouphail B; Dean RM; Hill BT; Jagadeesh D; Pohlman B; Hsi ED; Smith MR
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):797-803. PubMed ID: 28789937
[TBL] [Abstract][Full Text] [Related]
12. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
[TBL] [Abstract][Full Text] [Related]
13. Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era.
Chen Y; Luo L; Chen L; Zheng X; Yang X; Zheng Z; Zheng J; Liu T; Yang T; Hu J
J Cancer Res Clin Oncol; 2023 Jun; 149(6):2311-2318. PubMed ID: 36219261
[TBL] [Abstract][Full Text] [Related]
14. Follicular non-Hodgkin's lymphoma: correlation between histology, pathophysiology, cytogenetic, prognostic factors, treatment, survival.
Găman AM
Rom J Morphol Embryol; 2013; 54(1):71-6. PubMed ID: 23529311
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous rituximab in patients with diffuse large B cell lymphoma and follicular lymphoma: Final results of the non-interventional study MabSCale.
Dürig J; Uhlig J; Gerhardt A; Ritter M; Hapke G; Heßling J; Staib P; Wolff F; Krumm K; von Weikersthal LF
Cancer Med; 2023 Feb; 12(3):2739-2751. PubMed ID: 36017743
[TBL] [Abstract][Full Text] [Related]
16. Conjunctival Lymphoma--An International Multicenter Retrospective Study.
Kirkegaard MM; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Toft PB; Vemuganti GK; Thuro BA; Curtin J; Heegaard S
JAMA Ophthalmol; 2016 Apr; 134(4):406-14. PubMed ID: 26891973
[TBL] [Abstract][Full Text] [Related]
17. Impact of prior treatment on outcome of transformed follicular lymphoma and relapsed de novo diffuse large B cell lymphoma: a retrospective multicentre analysis.
Lerch K; Meyer AH; Stroux A; Hirt C; Keller U; Viardot A; Marks R; Schreiber S; Pezzutto A; Scholz CW
Ann Hematol; 2015 Jun; 94(6):981-8. PubMed ID: 25645656
[TBL] [Abstract][Full Text] [Related]
18. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
19. Standard R-CHOP therapy in follicular lymphoma and diffuse large B-cell lymphoma.
Tomita N; Takasaki H; Fujisawa S; Miyashita K; Ogusa E; Kishimoto K; Matsuura S; Sakai R; Koharazawa H; Yamamoto W; Fujimaki K; Fujita H; Ishii Y; Taguchi J; Kuwabara H; Motomura S; Ishigatsubo Y
J Clin Exp Hematop; 2013; 53(2):121-5. PubMed ID: 23995108
[TBL] [Abstract][Full Text] [Related]
20. Expression of "DNA damage response" pathway genes in diffuse large B-cell lymphoma: The potential for exploiting synthetic lethality.
Mansoor A; Kamran H; Rizwan H; Akhter A; Roshan TM; Shabani-Rad MT; Bavi P; Stewart D
Hematol Oncol; 2024 Jan; 42(1):e3225. PubMed ID: 37795760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
